The current achievements in treating glioblastoma (GBM) patients are not sufficient because
many challenges exist, such as tumor heterogeneity, the blood brain barrier, glioma stem
cells, drug efflux pumps and DNA damage repair mechanisms. Drug combination therapies
have shown increasing benefits against those challenges. With the help of nanocarriers,
enhancement of the efficacy and safety could be gained using synergistic combinations of
different therapeutic agents. In this review, we will discuss the major issues for GBM …